Company / Free Cash Flow
TherapeuticsMD, Inc. Free Cash Flow History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$55.2M
FY2022
5-year range
-$168.2M / -$55.2M
FY2018-FY2022
Trend
+67.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2022 after 3 years of decline, reaching -$55M.
Based on SEC 10-K filings.
-$55M in FY2022.
Improved from -$107M to -$55M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, free cash flow increased 67.2% year-over-year.
- Peak free cash flow was recorded in FY2015.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$55.2M | +67.2% |
| FY2021 | -$168.2M | -57.1% |
| FY2020 | -$107.0M | -40.4% |
| FY2019 | -$76.2M | -9.6% |
| FY2018 | -$69.5M | +12.2% |
| FY2017 | -$79.2M | -73.9% |
| FY2016 | -$45.6M | -118.9% |
| FY2015 | -$20.8M | -62.5% |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026